ANAB Stock Annual Cash Flow. Download in Excel
AnaptysBio Inc.
ANAB 
NGS
Sector: Healthcare
Industry: Biotechnology
23.97
USD
0.78
(3.36%)
Previous close: 23.19 Open: 23.42 Bid: 21.69 Ask: 23.97
52 week range
12.21 41.31
Mkt Cap: 704 M Avg Vol (90 Days): 749,050
Last updated: Wednesday 11th June 2025
Financials
ANAB Cash Flow
Annual
| Invalid date | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | Dec-23 | Dec-24 | |
|---|---|---|---|---|---|---|---|---|---|
| (Increase) Decrease in other current assets | 1 M | ||||||||
| (Increase) Decrease in other current liabilities | -876000.0 | -543000.0 | -5 M | -34 M | |||||
| (Increase) Decrease in payables | 2 M | 7 M | 14 M | -8 M | -5 M | 10 M | 11 M | -34 M | |
| (Increase) Decrease in receivables | 3 M | 1 M | 174000.0 | ||||||
| CapitalExpenditureReported | 290000.0 | 1 M | 805000.0 | 569000.0 | 1 M | ||||
| Cash at beginning of period | 51 M | 81 M | 114 M | 171 M | 251 M | 36 M | |||
| Cash at end of period | 81 M | 114 M | 171 M | 251 M | 496 M | -74 M | -425 M | 123 M | |
| Cash flow | -19 M | -49 M | -70 M | -14 M | -46 M | -74 M | -121 M | -135 M | |
| CashFlowFromContinuingInvestingActivities | -243 M | -142 M | 131 M | 94 M | 39 M | -395 M | 145 M | 95 M | |
| ChangeInAccountPayable | 2 M | 7 M | 14 M | -8 M | -5 M | 10 M | 11 M | -34 M | |
| ChangeInIncomeTaxPayable | 139000.0 | ||||||||
| ChangeInPayablesAndAccruedExpense | 2 M | 7 M | 14 M | -8 M | -5 M | 10 M | 11 M | -34 M | |
| ChangeInPrepaidAssets | -2 M | -5 M | 2 M | 1 M | -2 M | -813000.0 | -4 M | 3 M | |
| ChangeInTaxPayable | 139000.0 | ||||||||
| ChangeInWorkingCapital | 4 M | 3 M | 17 M | -7 M | -7 M | 8 M | 1 M | -65 M | |
| Depreciation | 183000.0 | 315000.0 | 514000.0 | 559000.0 | 619000.0 | 675000.0 | 652000.0 | 606000.0 | |
| Depreciation unreconciled | 183000.0 | -918000.0 | -2 M | 2 M | 2 M | 2 M | 2 M | 2 M | |
| DepreciationAndAmortization | 183000.0 | -918000.0 | -2 M | 2 M | 2 M | 2 M | 2 M | 2 M | |
| FinancingCashFlow | 292 M | 223 M | -4 M | -879000.0 | 252 M | 44 M | -59 M | 127 M | |
| Free cash flow | -20 M | -50 M | -70 M | -15 M | -47 M | -74 M | -121 M | -135 M | |
| GainLossOnInvestmentSecurities | 11000.0 | ||||||||
| InterestPaidSupplementalData | 1 M | 1 M | 424000.0 | 4000.0 | |||||
| Issuance of capital stock | 293 M | 227 M | 496000.0 | 3 M | |||||
| Issuance of debt | -7 M | -7 M | -1 M | ||||||
| IssuanceOfCapitalStock | 293 M | 227 M | 496000.0 | 3 M | |||||
| IssuanceOfDebt | -7 M | -7 M | -1 M | ||||||
| Net cash from financing activities | 292 M | 223 M | -4 M | -879000.0 | 252 M | 44 M | -59 M | 127 M | |
| Net cash from investing activities | -243 M | -142 M | 131 M | 94 M | 39 M | -395 M | 145 M | 95 M | |
| Net cash from operating activities | -19 M | -49 M | -70 M | -14 M | -46 M | -74 M | -121 M | -135 M | |
| Net change in cash & cash equivalents | 30 M | 32 M | 57 M | 79 M | 245 M | -424 M | -35 M | 87 M | |
| Net income from continuing operations | -30 M | -62 M | -97 M | -20 M | -58 M | -129 M | -164 M | -145 M | |
| NetCommonStockIssuance | 293 M | 227 M | 496000.0 | 3 M | |||||
| NetInvestmentPropertiesPurchaseAndSale | -243 M | -141 M | 132 M | 95 M | 40 M | -304 M | -380 M | ||
| NetInvestmentPurchaseAndSale | -243 M | -141 M | 132 M | 95 M | 40 M | -304 M | -380 M | ||
| NetIssuancePaymentsOfDebt | -7 M | -7 M | -1 M | ||||||
| NetPPEPurchaseAndSale | -290000.0 | -1 M | -805000.0 | -569000.0 | -1 M | ||||
| Operating (gains) losses | 11000.0 | ||||||||
| Other financing charges net | -2 M | -182000.0 | 250 M | ||||||
| Other non-cash items | 6 M | 11 M | 13 M | 11 M | 17 M | 44 M | 39 M | 72 M | |
| ProceedsFromIssuanceOfWarrants | 536000.0 | 76000.0 | |||||||
| ProceedsFromStockOptionExercised | 979000.0 | 3 M | 3 M | 500000.0 | |||||
| Purchase of Float term investments | -291 M | -348 M | -252 M | -195 M | -119 M | -304 M | -380 M | ||
| Purchase of property plant & equipment | -290000.0 | -1 M | -805000.0 | -569000.0 | -1 M | ||||
| PurchaseOfInvestment | -291 M | -348 M | -252 M | -195 M | -119 M | -304 M | -380 M | ||
| PurchaseOfPPE | -290000.0 | -1 M | -805000.0 | -569000.0 | -1 M | ||||
| RepaymentOfDebt | -7 M | -7 M | -1 M | ||||||
| Revenue per share | -1 M | -3 M | 1 M | 1 M | 2 M | 2 M | 2 M | ||
| Sale of short term investments | 48 M | 206 M | 384 M | 290 M | 159 M | ||||
| SaleOfInvestment | 48 M | 206 M | 384 M | 290 M | 159 M | ||||
| SaleOfPPE | 15000.0 | ||||||||
| ShortTermDebtPayments | -7 M | -7 M | -1 M | ||||||
| StockBasedCompensation | 4 M | 27 M | 33 M | 34 M | |||||
| UnrealizedGainLossOnInvestmentSecurities | 11000.0 | -1 M | 461000.0 | 493000.0 | -3 M | -11 M | -10 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.